Peck Madigan Jones (on Behalf of American Society of Clinical Oncology)
Professional organization for physicians and oncology professionals.
Based in DC
🤖
AI Overview
With $40K in lobbying spend across 6 quarterly filings, Peck Madigan Jones (on Behalf of American Society of Clinical Oncology) is an active lobbying client. Their lobbying covers 3 issue areas. Active from 2019 to 2020.
$40K
Total Spend
2
Years Active
1
Firms Hired
1
Lobbyists Deployed
3
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2019 | $40K |
| 2020 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, MED, Medicare/Medicaid
- •Issues related to cancer prevention, research, and treatment.
- •Issues related to oncology care, physician reimbursement, research funding, and the cost of prescription drugs
- •Issues related to oncology care, physician reimbursement, and the cost of prescription drugs
- •HR 913 - Clinical Treatment Act, MACRA implementation
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
American Clinical Laboratory Assn
$23.9M total spend
Ickes & Enright Group (Northwell Health FKA North Shore-lij)
$3.4M total spend
Association for Diagnostics & Laboratory Medicine (Formerly Aacc)
$2.8M total spend
The Biosimilars Forum
$2.6M total spend
National Association of Children's Hospitals
$1.8M total spend
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.